William Blair Issues Pessimistic Outlook for Merus Earnings

Merus (NASDAQ:MRUS) – Stock analysts at William Blair cut their Q3 2025 EPS estimates for shares of Merus in a report released on Monday, December 2nd. William Blair analyst M. Phipps now anticipates that the biotechnology company will post earnings of ($1.00) per share for the quarter, down from their previous estimate of ($0.99). The consensus estimate for Merus’ current full-year earnings is ($3.89) per share. William Blair also issued estimates for Merus’ Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($4.12) EPS, FY2026 earnings at ($3.97) EPS and FY2027 earnings at ($4.02) EPS.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The company had revenue of $11.77 million during the quarter, compared to the consensus estimate of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%.

MRUS has been the topic of several other research reports. Guggenheim restated a “buy” rating and issued a $109.00 target price (down previously from $111.00) on shares of Merus in a research note on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price objective on shares of Merus in a research note on Monday. The Goldman Sachs Group initiated coverage on shares of Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price for the company. UBS Group initiated coverage on Merus in a research report on Thursday, October 24th. They set a “buy” rating and a $72.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $85.00 price objective on shares of Merus in a research report on Monday. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $85.27.

Merus Price Performance

Shares of NASDAQ:MRUS opened at $46.21 on Wednesday. The business’s fifty day moving average price is $49.90 and its two-hundred day moving average price is $51.89. Merus has a fifty-two week low of $22.27 and a fifty-two week high of $61.61. The stock has a market capitalization of $3.16 billion, a price-to-earnings ratio of -11.70 and a beta of 1.07.

Institutional Investors Weigh In On Merus

Several institutional investors have recently modified their holdings of MRUS. nVerses Capital LLC boosted its stake in Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,500 shares during the last quarter. US Bancorp DE bought a new position in shares of Merus in the 3rd quarter worth $103,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 489 shares during the period. Farallon Capital Management LLC bought a new stake in Merus in the second quarter valued at about $237,000. Finally, ProShare Advisors LLC bought a new stake in Merus in the second quarter valued at about $242,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.